[REFERENCE TRANSLATION]
Please note that this translation is to be used solely as reference and the financial statements in this material are unaudited. In case of any discrepancy between this translation and the Japanese original, the latter shall prevail.
This translation is subject to change without notice. Linical Co., Ltd. shall accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding, or changes with regard to this translation.
Consolidated Financial Results | |
for the Nine Months Ended December 31, 2022 | |
(Japanese GAAP) | |
February 14, 2023 | |
Company name | :Linical Co., Ltd. |
Stock Listing | :Tokyo Stock Exchange |
Code No. | :2183 |
URL | :https://www.linical.co.jp/ |
Representative | :Kazuhiro Hatano, President & Chief Executive Officer |
Contact | :Akihiro Takahashi, Executive Vice President, Chief Financial Officer |
Scheduled date of filing of quarterly report | : February 14, 2023 | |||||||||||||||||||
Scheduled date of start of dividend payment | : - | |||||||||||||||||||
Preparation of supplementary materials for the quarterly | : No | |||||||||||||||||||
financial statements | ||||||||||||||||||||
Holding of presentation for the quarterly financial results | : No | |||||||||||||||||||
(All amounts are rounded down to the nearest million yen) | ||||||||||||||||||||
1.Consolidated Financial Results for the Nine Months Ended December 31, 2022 | ||||||||||||||||||||
(April 1, 2022 to December 31, 2022) | ||||||||||||||||||||
(1)Consolidated Financial Results (cumulative) | (% figures show year-on-year change) | |||||||||||||||||||
Net sales | Operating income | Ordinary income | Profit attributable to | |||||||||||||||||
owners of parent | ||||||||||||||||||||
Nine Months Ended | (¥ million) | change(%) | (¥ million) | change(%) | (¥ million) | change(%) | (¥ million) | change(%) | ||||||||||||
December 31, 2022 | 9,246 | 7.3 | 740 | △11.5 | 768 | △9.2 | 577 | 10.0 | ||||||||||||
December 31, 2021 | 8,613 | 14.4 | 836 | 302.9 | 846 | 683.8 | 524 | 234.1 | ||||||||||||
(Note) Comprehensive income | Nine Months Ended December 31, 2022: | ¥ 778 million (15.5%) | ||||||||||||||||||
Nine Months Ended December 31, 2021: | ¥673 million (278.8%) | |||||||||||||||||||
Net income per share | Diluted net income | |||||||||||||||||||
per share | ||||||||||||||||||||
Nine Months Ended | (¥) | (¥) | ||||||||||||||||||
December 31, 2022 | 25.57 | - | ||||||||||||||||||
December 31, 2021 | 23.24 | - | ||||||||||||||||||
(2)Consolidated Financial Position | ||||||||||||||||||||
Total assets | Net assets | Shareholders' | Net asset per | |||||||||||||||||
equity ratio | share | |||||||||||||||||||
(¥ million) | (¥ million) | |||||||||||||||||||
(%) | (¥) | |||||||||||||||||||
As of December 31, 2022 | 16,847 | 7,005 | 41.6 | 310.15 | ||||||||||||||||
As of March 31, 2022 | 15,716 | 6,543 | 41.6 | 289.69 | ||||||||||||||||
(Reference)Shareholder's equity: | As of December 31, 2022: | ¥7,005 million | ||||||||||||||||||
As of March 31, 2022: | ¥6,543 million |
2.Dividends | ||||||||||||||||||||
Annual dividends per share (¥) | ||||||||||||||||||||
1st Quarter End | 2nd Quarter End | 3rd Quarter End | Fiscal | Total | ||||||||||||||||
Year End | ||||||||||||||||||||
Year Ended March 31, 2022 | - | 0.00 | - | 14.00 | 14.00 | |||||||||||||||
Year Ending March 31, 2023 | - | 0.00 | - | |||||||||||||||||
Year Ending March 31, | 14.00 | 14.00 | ||||||||||||||||||
2023(Forecast) | ||||||||||||||||||||
(Note)Change in the dividend forecast from the most recent announcement: No | ||||||||||||||||||||
3.Forecast of Consolidated Financial Result for the Year Ending March 31, 2023 | ||||||||||||||||||||
(April 1, 2022 to March 31, 2023) | (% figures show year-on-year change) | |||||||||||||||||||
Profit attributable | Net income | |||||||||||||||||||
Net sales | Operating income | Ordinary income | to owners of | |||||||||||||||||
per share | ||||||||||||||||||||
parent | ||||||||||||||||||||
(¥ million) | % | (¥ million) | % | (¥ million) | % | (¥ million) | % | (¥) | ||||||||||||
Full year | 12,440 | 7.7 | 1,224 | 12.7 | 1,204 | 1.7 | 871 | 10.2 | 38.56 |
(Note)Change in forecasts of consolidated financial results from the most recent announcement: No
※ Notes | |||||
(1)Changes | in significant | subsidiaries during the period(changes in specified | :No | ||
subsidiaries that caused changes in scope of consolidation) | |||||
New: | - | (Company Name) | - | ||
Exclusion: | - | (Company Name) | - | ||
(2)Adoption | of | accounting | methods specific to the | preparation of quarterly | :No |
consolidated | financial statements |
(3)Changes in accounting policies, accounting estimates and restatements
1)Changes in accounting policies resulting from the revision of the accounting standards and other regulations
2)Changes in accounting policies other than 1) 3)Changes in accounting estimates 4)Restatements
(4)Number of issued shares (Common share)
(a)Number of issued shares at the end of the period (including treasury shares)
:Yes
:No
:No
:No
As of | December 31, 2022 |
As of | March 31, 2022 |
(b) Number of treasury shares at the end of the period
As of | December 31, 2022 |
As of | March 31, 2022 |
- Average number of shares during the period Nine Months Ended December 31, 2022 Nine Months Ended December 31, 2021
:24,740,000 shares
:24,740,000 shares
:2,153,564 shares
:2,153,564 shares
:22,586,436 shares
:22,586,436 shares
- This release is outside the scope of the external auditor's quarterly review procedure.
- Explanation on appropriate use of forecast and other special items
This material contains business forecast and other forward-looking statements which are based on available information and certain assumptions that are considered reasonable at the time of preparation. Various factors may cause actual results, etc. to be materially different from those expressed in these forward-looking statements.
Consolidated Balance Sheets
(Thousands of yen) | ||
As of March 31, 2022 | As of December 31, 2022 | |
Assets | ||
Current assets | ||
Cash and deposits | 5,985,618 | 6,753,942 |
Accounts receivable - trade and contrac | 2,917,990 | 3,051,295 |
Prepaid expenses | 197,784 | 254,522 |
Advances paid | 987,891 | 1,136,687 |
Other | 266,645 | 330,268 |
Allowance for doubtful accounts | △34,842 | △12,253 |
Total current assets | 10,321,087 | 11,514,462 |
Non-current assets | ||
Property, plant and equipment | 664,111 | 630,569 |
Intangible assets | ||
Goodwill | 3,406,633 | 3,401,590 |
Other | 159,249 | 134,186 |
Total intangible assets | 3,565,883 | 3,535,777 |
Investments and other assets | ||
Investment securities | 347,652 | 334,208 |
Long-term prepaid expenses | 5,461 | 1,470 |
Guarantee deposits | 366,280 | 372,956 |
Deferred tax assets | 445,992 | 458,410 |
Total investments and other assets | 1,165,387 | 1,167,045 |
Total non-current assets | 5,395,381 | 5,333,392 |
Total assets | 15,716,469 | 16,847,854 |
Consolidated Balance Sheets
(Thousands of yen) | ||
As of March 31, 2022 | As of December 31, 2022 | |
Liabilities | ||
Current liabilities | ||
Short-term borrowings | 600,000 | 600,000 |
Current portion of long-term borrowings | 539,976 | 539,976 |
Accounts payable - other | 533,842 | 689,794 |
Accrued expenses | 402,485 | 347,835 |
Income taxes payable | 193,650 | 146,549 |
Accrued consumption taxes | 38,747 | 96,763 |
Advances received | 2,147,272 | 2,443,595 |
Deposits received | 688,038 | 1,426,954 |
Provision for bonuses | 171,809 | 98,073 |
Other | 162,279 | 157,204 |
Total current liabilities | 5,478,102 | 6,546,746 |
Non-current liabilities | ||
Long-term borrowings | 2,533,566 | 2,128,584 |
Lease liabilities | 430,959 | 412,020 |
Retirement benefit liability | 689,644 | 721,531 |
Other | 41,028 | 33,770 |
Total non-current liabilities | 3,695,198 | 3,295,906 |
Total liabilities | 9,173,300 | 9,842,652 |
Net assets | ||
Shareholders' equity | ||
Share capital | 214,043 | 214,043 |
Retained earnings | 6,604,985 | 6,866,294 |
Treasury shares | △657,461 | △657,461 |
Total shareholders' equity | 6,161,567 | 6,422,876 |
Accumulated other comprehensive income | ||
Valuation difference on available-for- | 42,339 | 40,240 |
sale securities | ||
Foreign currency translation adjustment | 322,124 | 525,933 |
Remeasurements of defined benefit plans | 17,138 | 16,151 |
Total accumulated other comprehensive | 381,601 | 582,325 |
income | ||
Total net assets | 6,543,169 | 7,005,202 |
Total liabilities and net assets | 15,716,469 | 16,847,854 |
Consolidated statements of income (cumulative)
(Thousands of yen) | |||
Nine months ended | Nine months ended | ||
December 31, 2021 | December 31, 2022 | ||
Net sales | 8,613,651 | 9,246,539 | |
Cost of sales | 5,934,911 | 6,256,857 | |
Gross profit | 2,678,739 | 2,989,682 | |
Selling, general and administrative expenses | 1,842,072 | 2,249,346 | |
Operating profit | 836,666 | 740,336 | |
Non-operating income | |||
Interest income | 423 | 441 | |
Foreign exchange gains | 24,311 | 57,453 | |
Total non-operating income | 24,734 | 57,895 | |
Non-operating expenses | |||
Interest expenses | 10,979 | 9,962 | |
Loss on valuation of investment securities | 2,781 | 19,864 | |
Other | 1,561 | - | |
Total non-operating expenses | 15,322 | 29,826 | |
Ordinary profit | 846,079 | 768,404 | |
Extraordinary income | |||
Insurance claim income | - | 66,202 | |
Gain on liquidation of subsidiaries | - | 35,358 | |
Settlement recieved | 160,486 | - | |
Total extraordinary income | 160,486 | 101,560 | |
Extraordinary losses | |||
Arbitration related expenses | 136,594 | - | |
Information security expenses | 99,053 | - | |
Business restructuring expenses | - | 26,619 | |
Loss on cancellation of leases | - | 20,478 | |
Total extraordinary losses | 235,648 | 47,098 | |
Profit before income taxes | 770,917 | 822,867 | |
Income taxes - current | 230,399 | 239,607 | |
Income taxes - deferred | 15,623 | 5,739 | |
Total income taxes | 246,023 | 245,347 | |
Profit | 524,893 | 577,519 | |
Profit attributable to owners of parent | 524,893 | 577,519 | |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Linical Co. Ltd. published this content on 14 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 February 2023 07:49:01 UTC.